Liquidia Corporation
LQDA
Clasificación en acciones
#4681
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Precio por acción
$35.98
Capitalización bursátil
$3.22B
Cambio (1 día)
5.41%
Cambio (1 año)
47.20%
País
US
Comercio Liquidia Corporation (LQDA)
Categoría
Healthcare
Ganancias de Liquidia Corporation (LQDA)
Ganancias en Jun 2026 TTM: $149.50M
Secondo gli ultimi rapporti finanziari di Liquidia Corporation, gli utili attuali della società sono $149.50M. Nel 2023, la società ha registrato un utile di $-78.50M, una disminución en comparación con agli utili del 2022, che erano di $-41.02M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Liquidia Corporation desde 2016 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $149.50M | -214.65% |
| 2024 | $-130.39M | 66.10% |
| 2023 | $-78.50M | 91.40% |
| 2022 | $-41.02M | 18.61% |
| 2021 | $-34.58M | -42.14% |
| 2020 | $-59.76M | 25.60% |
| 2019 | $-47.58M | -10.45% |
| 2018 | $-53.14M | 82.26% |
| 2017 | $-29.15M | 82.97% |
| 2016 | $-15.93M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $1.35B | 802.91% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -82.36% |
US
|
